Literature DB >> 12532190

New directions in pain management.

Ross D MacPherson1.   

Abstract

Pain medicine is one of the most rapidly developing medical specialties of today. While there are many modalities that can be used in managing the patient in pain, drug treatment remains, for the most part, the cornerstone of treatment. Opioids retain their position as the foundation of most analgesic strategies, although they tend to be used nowadays in combination with adjuvant analgesics such as paracetamol and nonsteroidal antiinflammatory drugs. The range of available opioids has also been expanded with drugs such as hydromorphone and oxycodone, originally developed almost a century ago. This expanded choice has resulted in the concept of opioid rotation in chronic pain states, an approach that is aimed at maintaining pain control while minimizing adverse effects. Nonsteroidal antiinflammatory drugs continue to play an important role, especially as adjuvants, and the development of drugs such as celecoxib and refecoxib, highly specific for the inhibition of cyclooxygenase 2 pathway has been a further advance. The treatment of neuropathic pain continues to be a challenge to the clinician. While this has traditionally been treated with drugs from the anticonvulsant, antiarrhythmic and anti-depressant groups, results from these treatments have often been less than satisfactory. This has led to the development of completely new drug classes that modulate neuronal transmission in pain pathways, some of which are derived from exotic animal sources, such as the conotoxins from the marine snail family and epibatidine from a species of frog. The role of cannabinoids remains controversial.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12532190     DOI: 10.1358/dot.2002.38.2.668325

Source DB:  PubMed          Journal:  Drugs Today (Barc)        ISSN: 1699-3993            Impact factor:   2.245


  6 in total

1.  Mas-related G-protein-coupled receptors inhibit pathological pain in mice.

Authors:  Yun Guan; Qin Liu; Zongxiang Tang; Srinivasa N Raja; David J Anderson; Xinzhong Dong
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-19       Impact factor: 11.205

2.  Safe direct current stimulation to expand capabilities of neural prostheses.

Authors:  Gene Y Fridman; Charles C Della Santina
Journal:  IEEE Trans Neural Syst Rehabil Eng       Date:  2013-03       Impact factor: 3.802

3.  Potential for Cell-Transplant Therapy with Human Neuronal Precursors to Treat Neuropathic Pain in Models of PNS and CNS Injury: Comparison of hNT2.17 and hNT2.19 Cell Lines.

Authors:  Mary J Eaton; Yerko Berrocal; Stacey Q Wolfe
Journal:  Pain Res Treat       Date:  2012-04-24

4.  Increased methylation of the MOR gene proximal promoter in primary sensory neurons plays a crucial role in the decreased analgesic effect of opioids in neuropathic pain.

Authors:  Xue-Long Zhou; Li-Na Yu; Yin Wang; Li-Hui Tang; Yu-Nan Peng; Jun-Li Cao; Min Yan
Journal:  Mol Pain       Date:  2014-08-13       Impact factor: 3.395

5.  Non-Adherence to Pharmacotherapy: A Prospective Multicentre Study About Its Incidence and Its Causes Perceived by Chronic Pain Patients.

Authors:  Rute Sampaio; Luís Filipe Azevedo; Cláudia Camila Dias; José M Castro Lopes
Journal:  Patient Prefer Adherence       Date:  2020-02-19       Impact factor: 2.711

6.  Portuguese Version of the Intentional Non-Adherence Scale: Validation in a Population of Chronic Pain Patients.

Authors:  Rute Sampaio; Mariana Cruz; Simão Pinho; Cláudia Camila Dias; John Weinman; José M Castro Lopes
Journal:  Front Pharmacol       Date:  2021-07-19       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.